Developer docs
API playgroundTry for free, no card

Search company profiles

MAC Clinical Research

Full company profile

uuid000jc8l

Namestring
MAC Clinical Research
Legal namestring
MAC Research Limited
Websiteurl
macplc.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

MAC Clinical Research is a UK-based, full-service Contract Research Organisation that delivers end-to-end clinical trial services to pharmaceutical and biotechnology companies globally. The company owns and operates 8 dedicated research centres in the UK and an MHRA-accredited Early Phase Unit in Manchester (held continuously since 2016), supported by a global network of contracted investigator sites spanning Europe, North America, Asia Pacific, and the Middle East. Its service offering covers the full clinical lifecycle including project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, medical monitoring, GMP manufacturing and pharmacy, clinical pathology, bioanalytical services, PK/PD analysis, and metabolomics.

The platform is differentiated by its owned-site model combined with proprietary technology assets, including the CliniSafe concomitant-medication checking system (New Zealand patent granted 2013, SCRIP Award 2010) and the MAC EnVision Patient Engagement platform, which leverages a 250,000+ volunteer database and an AI-integrated recruitment software platform supported by a purpose-built national Recruitment Contact Centre. Specialised capabilities include Psychedelic Testing Suites (9 psychedelic studies completed), a Sleep Laboratory with polysomnography expertise, and Memory Assessment Research Clinics focused on dementia and Alzheimer's. These assets position MAC as one of Europe's largest CROs with particular depth in CNS, neuroscience, and psychedelic research.

MAC generates revenue through professional-services contracts with pharmaceutical and biotech sponsors, supplemented by managed-services revenue from its GMP Pharmacy and bioanalytical laboratories. Pricing is quote-based and not publicly disclosed, and the company sells primarily through direct enterprise field sales teams with thought-leadership support from podcasts, newsletters, webinars, and industry conferences. Notable named customers include Atai/Beckley, Initiator Pharma, Kariya Pharmaceuticals, Gilgamesh Pharma, and Newleos Therapeutics, predominantly in early-stage biotech. The company is privately held, founder-led (CEO Dr Mark Dale), and operates as MAC Research Limited.

Short descriptiontext

MAC Clinical Research is a UK-headquartered, full-service global CRO that owns 8 dedicated research sites, an MHRA-accredited Phase 1 unit, and a 250,000-volunteer database, serving pharmaceutical and biotech sponsors across CNS, psychedelic, and early-phase neuroscience trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBlackpool, United Kingdom
HQ citystring
Blackpool
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices30 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research organization, clinical trial services, patient recruitment, early phase studies, pharmaceutical research
Industry1 code
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Contract Research Organisation (CRO) Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Research Services
TypeProfessional Services
Description

Full-service contract research organisation providing end-to-end clinical trial services including project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, and medical monitoring for pharmaceutical and biotech companies

macplc.com
2Dedicated Research Site Services
TypeProfessional Services
Description

Owning and operating a network of dedicated research sites in the UK providing patient recruitment, retention, and clinical trial delivery services

macplc.com
3GMP Manufacturing & Pharmacy
TypeManaged Services
Description

Pharmaceutical manufacturing services including GMP pharmacy for clinical trial IMP production, clinical pathology, bioanalytical services, PK/PD analysis, and metabolomics

macplc.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1MAC: Behind The Trials
Description

A video podcast series featuring conversations with MAC experts on clinical research topics

macplc.com
+2 more records
Core offering1 text field

MAC Clinical Research is a full-service, global Contract Research Organisation that provides end-to-end clinical trial services to pharmaceutical and biotechnology sponsors. The company owns and operates a network of dedicated research sites across the UK and an MHRA-accredited Early Phase Unit in Manchester, supported by a proprietary volunteer database of over 250,000 registered participants. Its offering spans project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, medical monitoring, GMP manufacturing, bioanalytical services, patient recruitment, and specialised neuroscience and psychedelic trial capabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 80 people Clinical Research Services department providing full CRO services
+1 more record
Product overview1 text field

MAC Clinical Research operates as a full-service, global Contract Research Organisation (CRO) with a platform-plus-services architecture. The company owns and operates a network of Dedicated Research Sites across the UK, supported by an MHRA-accredited Early Phase Unit in Manchester. Core services span the complete clinical trial lifecycle including clinical operations, regulatory affairs, biometrics, pharmacovigilance, and pharmaceutical services. Specialized offerings include a Sleep Laboratory, Psychedelic Testing Suites, and Memory Assessment Research Clinics. The company provides patient recruitment through its MAC EnVision Patient Engagement platform using AI-integrated technology. GMP Pharmacy Manufacturing offers pharmaceutical production capabilities. A proprietary software product, CliniSafe, provides concomitant medication checking. The portfolio also includes digital solutions, remote clinical trial support, adaptive trial designs, and metabolomics services.

Product and service3 records
1Full-Service CRO Services
CategoryContract Research Services
Description

End-to-end clinical trial services including project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, vendor management, feasibility, and medical monitoring for pharmaceutical and biotech sponsors.

2Dedicated Research Sites
CategorySite Network Services
Description

Fully owned and operated network of 8 dedicated clinical research sites across the UK providing patient recruitment, retention, and trial delivery with direct sponsor oversight.

3Early Phase Unit (Phase 1)
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

MAC Clinical Research reached a key milestone dosing first patient in Phase 1b study sponsored by Newleos Therapeutics investigating NTX-1955 for Generalised Anxiety Disorder.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

MAC Clinical Research announced positive topline results from AtaiBeckley's exploratory Phase 2a clinical trial evaluating an investigational compound for Social Anxiety Disorder.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

MAC Clinical Research partnered with Gilgamesh Pharma in successful completion of Phase 2a clinical trial for Major Depressive Disorder with positive topline results announced.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

MAC Clinical Research serves as full-service CRO partner and funding partner for Initiator Pharma's Phase 2a vulvodynia trial (IP2015). MAC entered a convertible credit agreement to support the trial's delivery. Study is being conducted at MAC's UK research sites exploring safety, tolerability, and early signs of efficacy using a crossover design.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

MAC Clinical Research successfully delivered Phase I clinical trial for KP405, a brain-penetrant GLP-1/GIP analogue designed to slow progression of Parkinson's disease. Study confirmed KP405 was safe, well-tolerated and demonstrated behaviour consistent with GLP-1 drugs linked to positive outcomes in Parkinson's and Alzheimer's research.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-01
Description

Australian clinical site network company with multiple sites on East coast of Australia offering early and late phase clinical trials. Jude Warburton met with Paratus during AusBiotech 2023 to establish new relationships.

7UniSc Clinical Trials
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-01
Description

Australian clinical site network company with multiple sites on East coast of Australia. Visited two clinical sites in Brisbane and met their clinical teams during AusBiotech 2023 networking.

macplc.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-11-01
Description

FIH 32 bed site located in Sydney, keen to collaborate with MAC. Met during AusBiotech 2023 conference.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global top-5 CRO providing full-service clinical development, labs, and consulting. Competes with MAC for biotech and pharma study awards across all phases, with broader geographic and therapeutic coverage.

TypeBroad incumbent
Description

Large global CRO (now private-equity owned) offering end-to-end clinical development. Competes with MAC for full-service biotech mandates and offers broader geographic and operational scale.

TypeBroad incumbent
Description

World's largest CRO and life sciences services provider. Overlaps with MAC across full-service clinical operations, biometrics, and lab services, but operates at vastly greater scale and breadth.

TypeDirect peer
Description

London-based Phase I/early-phase CRO operating a dedicated clinical pharmacology unit. Directly comparable to MAC's Manchester Early Phase Unit for First-in-Human and Phase I studies in healthy volunteers.

TypeDirect peer
Description

Mid-sized, profitable full-service CRO focused on small and mid-sized biotech sponsors across all phases. Comparable to MAC in customer profile (biotech-centric) and therapeutic-area depth, with a broader geographic footprint.

TypeBroad incumbent
Description

Major CRO and preclinical/research-models provider with established early-phase clinical services. Comparable to MAC in lab services, early-phase and bioanalytical offerings, and biotech customer base.

TypeDirect peer
Description

UK-based specialist CRO with MHRA-accredited Phase I unit focused on early-phase clinical pharmacology. Closely matches MAC's early-phase clinical pharmacology, FIH, and CNS-adjacent capabilities.

TypeDirect peer
Description

UK-headquartered, mid-sized full-service CRO with particular strength in oncology and rare disease. Comparable to MAC as a similarly-sized, UK-rooted CRO competing for European biotech Phase I–III work, and historically known for its own site network model.

TypeDirect peer
Description

Mid-sized global CRO with strong CNS/neuroscience and rare disease franchises. Comparable to MAC in therapeutic-area mix (CNS-heavy) and positioning as a mid-tier alternative to mega-CROs.

TypeDirect peer
Description

Asia-Pacific-headquartered mid-sized CRO with global expansion into the US and Europe. Comparable to MAC as a regionally-rooted, mid-sized full-service CRO competing globally with biotech sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MAC Clinical Research

Contract Research Organisation (CRO) Servicesmacplc.com

MAC Clinical Research is a UK-headquartered, full-service global CRO that owns 8 dedicated research sites, an MHRA-accredited Phase 1 unit, and a 250,000-volunteer database, serving pharmaceutical and biotech sponsors across CNS, psychedelic, and early-phase neuroscience trials.

What MAC Clinical Research does

MAC Clinical Research is a UK-based, full-service Contract Research Organisation that delivers end-to-end clinical trial services to pharmaceutical and biotechnology companies globally. The company owns and operates 8 dedicated research centres in the UK and an MHRA-accredited Early Phase Unit in Manchester (held continuously since 2016), supported by a global network of contracted investigator sites spanning Europe, North America, Asia Pacific, and the Middle East. Its service offering covers the full clinical lifecycle including project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, medical monitoring, GMP manufacturing and pharmacy, clinical pathology, bioanalytical services, PK/PD analysis, and metabolomics.

The platform is differentiated by its owned-site model combined with proprietary technology assets, including the CliniSafe concomitant-medication checking system (New Zealand patent granted 2013, SCRIP Award 2010) and the MAC EnVision Patient Engagement platform, which leverages a 250,000+ volunteer database and an AI-integrated recruitment software platform supported by a purpose-built national Recruitment Contact Centre. Specialised capabilities include Psychedelic Testing Suites (9 psychedelic studies completed), a Sleep Laboratory with polysomnography expertise, and Memory Assessment Research Clinics focused on dementia and Alzheimer's. These assets position MAC as one of Europe's largest CROs with particular depth in CNS, neuroscience, and psychedelic research.

MAC generates revenue through professional-services contracts with pharmaceutical and biotech sponsors, supplemented by managed-services revenue from its GMP Pharmacy and bioanalytical laboratories. Pricing is quote-based and not publicly disclosed, and the company sells primarily through direct enterprise field sales teams with thought-leadership support from podcasts, newsletters, webinars, and industry conferences. Notable named customers include Atai/Beckley, Initiator Pharma, Kariya Pharmaceuticals, Gilgamesh Pharma, and Newleos Therapeutics, predominantly in early-stage biotech. The company is privately held, founder-led (CEO Dr Mark Dale), and operates as MAC Research Limited.

MAC Clinical Research firmographics

Firmographics
Name
MAC Clinical Research
Legal name
MAC Research Limited
Website
https://macplc.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
251–500 employees
Short description
MAC Clinical Research is a UK-headquartered, full-service global CRO that owns 8 dedicated research sites, an MHRA-accredited Phase 1 unit, and a 250,000-volunteer database, serving pharmaceutical and biotech sponsors across CNS, psychedelic, and early-phase neuroscience trials.
Ownership category
akta.pro rank

MAC Clinical Research industry classification

Industry
Product category
Contract Research Organisation (CRO) Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Contract research organization
  • Clinical trial services
  • Patient recruitment
  • Early phase studies
  • Pharmaceutical research

Where MAC Clinical Research is headquartered

Location

Headquarters

HQ city
Blackpool
HQ country
United Kingdom
HQ region
Europe

Offices30 records

Markets served

MAC Clinical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Clinical Research Services: Full-service contract research organisation providing end-to-end clinical trial services including project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, and medical monitoring for pharmaceutical and biotech companies
  2. Dedicated Research Site Services: Owning and operating a network of dedicated research sites in the UK providing patient recruitment, retention, and clinical trial delivery services
  3. GMP Manufacturing & Pharmacy: Pharmaceutical manufacturing services including GMP pharmacy for clinical trial IMP production, clinical pathology, bioanalytical services, PK/PD analysis, and metabolomics

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

MAC Clinical Research product offering

Product offering

Core offering

MAC Clinical Research is a full-service, global Contract Research Organisation that provides end-to-end clinical trial services to pharmaceutical and biotechnology sponsors. The company owns and operates a network of dedicated research sites across the UK and an MHRA-accredited Early Phase Unit in Manchester, supported by a proprietary volunteer database of over 250,000 registered participants. Its offering spans project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, medical monitoring, GMP manufacturing, bioanalytical services, patient recruitment, and specialised neuroscience and psychedelic trial capabilities.

Product overview

MAC Clinical Research operates as a full-service, global Contract Research Organisation (CRO) with a platform-plus-services architecture. The company owns and operates a network of Dedicated Research Sites across the UK, supported by an MHRA-accredited Early Phase Unit in Manchester. Core services span the complete clinical trial lifecycle including clinical operations, regulatory affairs, biometrics, pharmacovigilance, and pharmaceutical services. Specialized offerings include a Sleep Laboratory, Psychedelic Testing Suites, and Memory Assessment Research Clinics. The company provides patient recruitment through its MAC EnVision Patient Engagement platform using AI-integrated technology. GMP Pharmacy Manufacturing offers pharmaceutical production capabilities. A proprietary software product, CliniSafe, provides concomitant medication checking. The portfolio also includes digital solutions, remote clinical trial support, adaptive trial designs, and metabolomics services.

Differentiator

Problem solved

Functional benefit

Brands

  • MAC: Behind The Trials: A video podcast series featuring conversations with MAC experts on clinical research topics
  • CliniSafe
  • MAC EnVision

Products and services

  • Full-Service CRO Services End-to-end clinical trial services including project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, vendor management, feasibility, and medical monitoring for pharmaceutical and biotech sponsors.
  • Dedicated Research Sites Fully owned and operated network of 8 dedicated clinical research sites across the UK providing patient recruitment, retention, and trial delivery with direct sponsor oversight.
  • Early Phase Unit (Phase 1)

Quantifiable outcome

  • 80 people Clinical Research Services department providing full CRO services
  • +1 more outcomes

Companies that use MAC Clinical Research

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

MAC Clinical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MAC Clinical Research partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Newleos TherapeuticscoreStrategic or Co-development Partner · 1 April 2026MAC Clinical Research reached a key milestone dosing first patient in Phase 1b study sponsored by Newleos Therapeutics investigating NTX-1955 for Generalised Anxiety Disorder.
  • Atai/BeckleycoreStrategic or Co-development Partner · 1 March 2026MAC Clinical Research announced positive topline results from AtaiBeckley's exploratory Phase 2a clinical trial evaluating an investigational compound for Social Anxiety Disorder.
  • Gilgamesh PharmacoreStrategic or Co-development Partner · 1 February 2026MAC Clinical Research partnered with Gilgamesh Pharma in successful completion of Phase 2a clinical trial for Major Depressive Disorder with positive topline results announced.
  • Initiator PharmacoreStrategic or Co-development Partner · 1 November 2025MAC Clinical Research serves as full-service CRO partner and funding partner for Initiator Pharma's Phase 2a vulvodynia trial (IP2015). MAC entered a convertible credit agreement to support the trial's delivery. Study is being conducted at MAC's UK research sites exploring safety, tolerability, and early signs of efficacy using a crossover design.
  • Kariya PharmaceuticalscoreStrategic or Co-development Partner · 1 October 2025MAC Clinical Research successfully delivered Phase I clinical trial for KP405, a brain-penetrant GLP-1/GIP analogue designed to slow progression of Parkinson's disease. Study confirmed KP405 was safe, well-tolerated and demonstrated behaviour consistent with GLP-1 drugs linked to positive outcomes in Parkinson's and Alzheimer's research.
  • ParatusminorChannel Partner/ Reseller/ Distributor · 1 November 2023Australian clinical site network company with multiple sites on East coast of Australia offering early and late phase clinical trials. Jude Warburton met with Paratus during AusBiotech 2023 to establish new relationships.
  • UniSc Clinical TrialsminorChannel Partner/ Reseller/ Distributor · 1 November 2023Australian clinical site network company with multiple sites on East coast of Australia. Visited two clinical sites in Brisbane and met their clinical teams during AusBiotech 2023 networking.
  • Scientia Clinical ResearchminorChannel Partner/ Reseller/ Distributor · 1 November 2023FIH 32 bed site located in Sydney, keen to collaborate with MAC. Met during AusBiotech 2023 conference.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

MAC Clinical Research competitors and assessment

Company assessment

Broad incumbents

  • ICON plc: Global top-5 CRO providing full-service clinical development, labs, and consulting. Competes with MAC for biotech and pharma study awards across all phases, with broader geographic and therapeutic coverage.
  • Parexel International: Large global CRO (now private-equity owned) offering end-to-end clinical development. Competes with MAC for full-service biotech mandates and offers broader geographic and operational scale.
  • IQVIA: World's largest CRO and life sciences services provider. Overlaps with MAC across full-service clinical operations, biometrics, and lab services, but operates at vastly greater scale and breadth.
  • Charles River Laboratories: Major CRO and preclinical/research-models provider with established early-phase clinical services. Comparable to MAC in lab services, early-phase and bioanalytical offerings, and biotech customer base.

Direct peers

  • Hammersmith Medicines Research: London-based Phase I/early-phase CRO operating a dedicated clinical pharmacology unit. Directly comparable to MAC's Manchester Early Phase Unit for First-in-Human and Phase I studies in healthy volunteers.
  • Medpace: Mid-sized, profitable full-service CRO focused on small and mid-sized biotech sponsors across all phases. Comparable to MAC in customer profile (biotech-centric) and therapeutic-area depth, with a broader geographic footprint.
  • Richmond Pharmacology: UK-based specialist CRO with MHRA-accredited Phase I unit focused on early-phase clinical pharmacology. Closely matches MAC's early-phase clinical pharmacology, FIH, and CNS-adjacent capabilities.
  • Ergomed plc: UK-headquartered, mid-sized full-service CRO with particular strength in oncology and rare disease. Comparable to MAC as a similarly-sized, UK-rooted CRO competing for European biotech Phase I–III work, and historically known for its own site network model.
  • Worldwide Clinical Trials: Mid-sized global CRO with strong CNS/neuroscience and rare disease franchises. Comparable to MAC in therapeutic-area mix (CNS-heavy) and positioning as a mid-tier alternative to mega-CROs.
  • Novotech: Asia-Pacific-headquartered mid-sized CRO with global expansion into the US and Europe. Comparable to MAC as a regionally-rooted, mid-sized full-service CRO competing globally with biotech sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

MAC Clinical Research social profiles

Digital presence

MAC Clinical Research compliance and trust

Trust signal

Compliance9 records

MAC Clinical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MAC Clinical Research leadership team

Management profile

Number of profiles

Profiles16 records

MAC Clinical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MAC Clinical Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MAC Clinical Research

What does MAC Clinical Research do?

MAC Clinical Research is a full-service, global Contract Research Organisation that provides end-to-end clinical trial services to pharmaceutical and biotechnology sponsors. The company owns and operates a network of dedicated research sites across the UK and an MHRA-accredited Early Phase Unit in Manchester, supported by a proprietary volunteer database of over 250,000 registered participants. Its offering spans project management, clinical operations, regulatory affairs, biometrics, pharmacovigilance, medical monitoring, GMP manufacturing, bioanalytical services, patient recruitment, and specialised neuroscience and psychedelic trial capabilities.

Is MAC Clinical Research a public or private company?

MAC Clinical Research is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MAC Clinical Research founded?

MAC Clinical Research was founded in 2002. It employs 251 to 500 people.

Where is MAC Clinical Research based?

MAC Clinical Research is headquartered in Blackpool, United Kingdom, in the Europe region.

How does MAC Clinical Research make money?

Three revenue lines are on record. Clinical Research Services are the primary driver. The others are dedicated Research Site Services and GMP Manufacturing & Pharmacy.

Who are MAC Clinical Research's main competitors?

Broad incumbents on record are ICON plc, Parexel International, IQVIA and Charles River Laboratories. Direct peers are Hammersmith Medicines Research, Medpace, Richmond Pharmacology, Ergomed plc, Worldwide Clinical Trials and Novotech.

Does MAC Clinical Research have an API?

No public API is recorded for MAC Clinical Research.

What industry is MAC Clinical Research in?

MAC Clinical Research's product category is Contract Research Organisation (CRO) Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination. Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comTrends in Growth, Segment Analysis, and Competitive Strategies Influencing the Clinical Trial Investigative Site Network MarketThe clinical trial investigative site network market is projected to grow to $13.01 billion by 2030, driven by demand for decentralized trials, digital patient engagement tools, and adaptive trial designs. In January 2025, UK-based Medical Research Network Limited announced the acquisition of Volunteer Centre for Trials & Clinical Research (VCTC) to expand its UK presence and enhance decentralized clinical research capabilities. The article also notes a November 2023 partnership between Humana Inc. and durable medical equipment providers AdaptHealth Corp. and Rotech Healare Inc. for Medicare Advantage members.LinkedInNeurology M&A: Is it a hot target now?Kariya Pharmaceuticals announced the successful completion of a Phase I clinical trial for KP405, a brain-penetrating dual GLP-1/GIP receptor agonist designed to treat Parkinson's disease. The study, conducted by strategic partner MAC Clinical Research in the UK, demonstrated that the drug is safe and well-tolerated across 88 participants. Kariya plans to advance KP405 into Phase II trials next year, positioning it as a potential first-to-market treatment in this emerging drug class.LinkedInAre Decentralised Trials Really the Future of Clinical Research?MAC Clinical Research published an analysis arguing that while decentralised clinical trials (DCTs) offer significant benefits in participant access and efficiency, they face substantial regulatory and technological hurdles. The article concludes that hybrid models, combining remote capabilities with traditional site-based oversight, represent the most viable path forward for the industry rather than a full replacement of conventional methods.UNILADDoctor reveals how to know if your cough could be deadly and when you really should get helpDr. Malathy Munisamy from MAC Clinical Research outlined the distinctions between acute, subacute, and chronic coughs to help patients determine when medical attention is necessary. The guidance advises seeking professional care for symptoms lasting longer than three weeks or those accompanied by warning signs such as wheezing, fever over 101.5°F, or coughing up blood.GlobeNewswireFirst Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028Small Pharma confirmed the first subject was dosed in a Phase I trial of SPL028, its deuterated DMT candidate, in healthy volunteers. The randomized, placebo-controlled study compares intravenous and intramuscular administration at MAC Clinical Research in Manchester, England. Results will inform dose and route selection for a future patient study.PR NewswireDemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UKDemeRx IB, Inc. has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002) for the treatment of opioid use disorder, representing the first clinical trial of ibogaine for OUD in the UK. The trial, to be conducted at MAC Clinical Research in Manchester, will assess safety in recreational drug users before advancing to efficacy evaluation in opioid-dependent patients. The approval enables DemeRx to move beyond previously published uncontrolled studies into well-designed, controlled studies as part of regulatory processes.news.cision.comInitiator Pharma secures funding for IPED2015 clinical Phase 2b study - signs financing agreement with MAC Clinical Research worth up to 23 MSEKInitiator Pharma signed a convertible credit agreement with MAC Clinical Research worth up to 23 MSEK to fund a Phase 2b study of IPED2015 for erectile dysfunction. The study targets PDE5i nonresponders and is planned for H1 2021, with MAC converting debt into shares at 7.5 SEK per share.GlobeNewswireMAC Clinical Research Announces Presentation at the 60th Annual Scientific Meeting of the American Headache SocietyMAC Clinical Research presented trial data at the 60th Annual Scientific Meeting of the American Headache Society, showing glyceryl trinitrate (GTN) reproducibly induced migraine-like headaches in 20 healthy migraine patients. The delayed headache occurred in 75% of GTN-exposed patients versus none on placebo, and was treated with 5-HT agonists. The study suggests the model can efficiently test investigational migraine treatments.